Compare AMPX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | PHVS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | AMPX | PHVS |
|---|---|---|
| Price | $7.84 | $26.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $13.33 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 5.4M | 475.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,408,000.00 | N/A |
| Revenue This Year | $205.06 | N/A |
| Revenue Next Year | $127.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.14 | N/A |
| 52 Week Low | $1.70 | $11.51 |
| 52 Week High | $16.03 | $29.80 |
| Indicator | AMPX | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 31.59 | 53.90 |
| Support Level | $8.77 | $25.27 |
| Resistance Level | $11.58 | $26.09 |
| Average True Range (ATR) | 0.69 | 1.20 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 1.46 | 66.98 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.